Doximity, Inc.

NYSE:DOCS Voorraadrapport

Marktkapitalisatie: US$4.6b

Doximity Toekomstige groei

Future criteriumcontroles 2/6

Doximity zal naar verwachting groeien in winst en omzet met respectievelijk 4% en 7% per jaar. De winst per aandeel zal naar verwachting groeien met 3.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 30.2% zijn.

Belangrijke informatie

4.0%

Groei van de winst

3.65%

Groei van de winst per aandeel

Healthcare Services winstgroei21.5%
Inkomstengroei7.0%
Toekomstig rendement op eigen vermogen30.19%
Dekking van analisten

Good

Laatst bijgewerkt01 May 2026

Recente toekomstige groei-updates

Recent updates

Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack

Apr 28

DOCS: Healthcare Moat And AI Tools Will Support Future Engagement

The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.

DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement

The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.

DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook

Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.

DOCS: AI Tools And Share Buybacks Will Drive Shares Higher

Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.

DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook

The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.

DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher

Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.

Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

Feb 06
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement

Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.

DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement

Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.

DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher

We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.

DOCS: Budget Flush And Ad Shift Will Drive Shares Higher

Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.

Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Nov 14
Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks

Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.

At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Sep 02
At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve

Aug 15
We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.

Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely

Jul 08
Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely

With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case

Jun 23
With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case

At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

May 17
At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

May 01
Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value

Apr 04
Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value

What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You

Feb 23
What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You

Doximity Q3 Earnings: Outpacing Even Management's Expectations

Feb 10

When Should You Buy Doximity, Inc. (NYSE:DOCS)?

Jan 24
When Should You Buy Doximity, Inc. (NYSE:DOCS)?

Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution

Jan 13

Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching

Jan 06
Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Dec 06

Doximity (NYSE:DOCS) Knows How To Allocate Capital

Dec 01
Doximity (NYSE:DOCS) Knows How To Allocate Capital

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Nov 13
Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02
Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 15
Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Oct 03

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Sep 23
Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
User avatar

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion.

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18
There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Winst- en omzetgroeiprognoses

NYSE:DOCS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/20297932553633734
3/31/202876223336036916
3/31/202769720632532922
3/31/202664420930831322
12/31/2025638239307315N/A
9/30/2025621253312320N/A
6/30/2025590235287294N/A
3/31/2025570223267273N/A
12/31/2024550201232239N/A
9/30/2024517174217224N/A
6/30/2024494161162168N/A
3/31/2024475148178184N/A
12/31/2023468138162167N/A
9/30/2023448123160165N/A
6/30/2023437119186192N/A
3/31/2023419113173180N/A
12/31/2022402119173180N/A
9/30/2022384141151159N/A
6/30/2022362148131138N/A
3/31/2022344133121127N/A
12/31/2021317107113117N/A
9/30/202127757110114N/A
6/30/202124330103107N/A
3/31/2021207227883N/A
12/31/2020177144853N/A
3/31/2020116112226N/A
3/31/2019861N/A15N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DOCS ( 4% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van DOCS ( 4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.1% per jaar).

Hoge groeiwinsten: De winst van DOCS zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van DOCS ( 7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.3% per jaar).

Hoge groei-inkomsten: De omzet van DOCS ( 7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen DOCS zal naar verwachting over 3 jaar hoog zijn ( 30.2 %)

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/05 06:40
Aandelenkoers aan het einde van de dag2026/05/05 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Doximity, Inc. wordt gevolgd door 32 analisten. 22 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Vikram KesavabhotlaBaird
Glen SantangeloBarclays
Nisala WeerasuriyaBerenberg